Exact up on earlier colon cancer screening recommendation

Exact Sciences Corp. (NASDAQ:EXAS) jumped $5.86 (11%) to $58.58 on May 30 when the American Cancer Society (ACS) issued updated guidelines recommending that screening for colorectal cancer start earlier. Exact markets Cologuard, a non-invasive stool DNA test for colorectal cancer. The company gained more than $700 million in market cap with the move, and closed the week of May 28 up $7.72 (15%) to $59.54.

ACS now recommends adults ages 45 and older with an average risk of colorectal cancer undergo regular screening with either a high-sensitivity stool-based test or a structural examination, depending on patient preference and test availability. ACS previously recommended screening start at age 50...